Ionis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Alumis Inc.

University of Utah Research Foundation

Biogen Ma Inc.

Cold Spring Harbor Laboratory

Sichuan Haisco Pharmaceutical Co., Ltd.

Fronthera U.S. Pharmaceuticals LLC

Xizang Haisco Pharmaceutical Co., Ltd.

Other

Chdi Foundation, Inc.

Esker Therapeutics, Inc.

Gene Hung

C Frank Bennett

Susan M Freier

Qing Dong

Bohan Jin

Seng H Cheng

Lamya S Shihabuddin

Holly Kordasiewicz

Don W Cleveland

Lisa Stanek

Stephen W Kaldor

Frank Rigo

Eric E Swayze

Marco A Passini

Stefan M Pulst

Adrian R Krainer

Katherine W Klinger

Daniel R Scoles

Yao Li

Janet M Leeds

Yimin Hua

Hien Thuy Zhao

Kenneth W Dobie

C Frank Bennet

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Thyroid hormone receptor agonists and uses thereof

Described herein are compounds, for example, substituted 1,2,4-triazoles, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as TYK2 inhibitors

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.

Modulation of huntingtin expression

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted pyridazines as TYK2 inhibitors

The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.

Methods and compositions for inhibiting PMP22 expression

Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.

Compositions for modulating Ataxin 2 expression

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TY-K2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Modulation of Huntington expression

Described herein are pyridine compounds of Formula (XIII) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation 

Substituted pyridines as TYK2 inhibitors

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.

Autotaxin inhibitors and uses thereof

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Apoptosis signal-regulating kinase inhibitors and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Gene Hung